SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-365280"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-365280" > Effects of Teripara...

Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice : 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo (R) Observational Study (ExFOS)

Napoli, Nicola (författare)
Univ Campus Biomed, Div Endocrinol & Diabet, Alvaro del Portillo 21, I-00128 Rome, Italy
Langdahl, Bente. L. (författare)
Aarhus Univ Hosp, Aarhus, Denmark
Ljunggren, Östen (författare)
Uppsala universitet,Endokrinologi och mineralmetabolism
visa fler...
Lespessailles, Eric (författare)
Univ Orleans, Orleans, France;Reg Hosp Orleans, Orleans, France
Kapetanos, George (författare)
Papageorgiou Gen Hosp, Thessaloniki, Greece
Kocjan, Tomaz (författare)
Univ Med Ctr, Ljubljana, Slovenia
Nikolic, Tatjana (författare)
Univ Hosp, Zagreb, Croatia
Eiken, Pia (författare)
Hillerod Hosp, Dept Cardiol Nephrol & Endocrinol, Hillerod, Denmark;Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark
Petto, Helmut (författare)
Eli Lilly & Co, Windlesham, Surrey, England
Moll, Thomas (författare)
Eli Lilly & Co, Windlesham, Surrey, England
Lindh, Erik (författare)
Eli Lilly & Co, Windlesham, Surrey, England
Marin, Fernando (författare)
Eli Lilly & Co, Windlesham, Surrey, England
visa färre...
 (creator_code:org_t)
SPRINGER, 2018
2018
Engelska.
Ingår i: ; 103:4, s. 359-371
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • This study aimed to describe clinical outcomes in patients prescribed teriparatide and followed up for 18months after stopping the drug in real-life conditions. The Extended Forsteo (R) Observational Study analysed incident clinical fractures in 6-month intervals using logistic regression with repeated measures. Changes in back pain (visual analogue scale) and health-related quality of life (HRQoL; EQ-5D questionnaire) were analysed using mixed models for repeated measures. Patients were analysed if they had a post-baseline visit, regardless of whether and for how long they took teriparatide. Of 1531 patients analysed (90.7% female, mean age: 70.3years), 76 (5.0%) never took teriparatide. Median treatment duration was 23.6months. The adjusted odds of clinical fracture decreased by 47% in the >12- to 18-month treatment period (p=0.013) compared with the first 6-month period, with no statistically significant reduction in the >18- to 24-month interval. The clinical fracture rate remained stable during the 18 months' post-teriparatide, when approximately 98% of patients took osteoporosis medication (51% bisphosphonates). Clinical vertebral fractures were reduced at every time period compared with the first 6months. Adjusted mean back pain scores decreased and EQ-5D scores increased significantly at each post-baseline observation. In a real-life clinical setting, the risk of clinical fractures declined during 24months of teriparatide treatment. This reduction was maintained 18months after stopping teriparatide. In parallel, patients reported significant improvements in back pain and HRQoL. The results should be interpreted in the context of the non-controlled design of this observational study.

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Back pain
Fracture
Observational study
Osteoporosis
Quality of life
Teriparatide

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy